TB-500: Benefits, Dosage & FDA Status
Thymosin Beta-4 Fragment
A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
FDA Status
Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026)
Typical Dose
2 mg twice weekly (subcutaneous)
Evidence Grade
BLimited clinical + robust preclinical evidence
Half-Life
~2 hours (active fragment)
Routes of Administration
subcutaneous, intramuscular
First Synthesized
1981
Clinics Indexed
183 providers have offered TB-500 in our tracked directory.
Mechanism of Action
Sequesters G-actin to enable cytoskeletal remodeling; promotes endothelial cell migration and angiogenesis.
Key Reported Benefits
- ✓Wound healing
- ✓Anti-inflammation
- ✓Tissue regeneration
- ✓Flexibility
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.
Reported Side Effects
- •Lethargy (transient)
- •Head-rush at higher doses
- •Injection-site soreness
Contraindications
- ⚠Active malignancy
- ⚠Pregnancy / breastfeeding
Commonly Stacked With
Regulatory & Safety Context
FDA status: Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on TB-500. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
PDA
C+A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
BPC-157
B+A 15-amino-acid peptide derived from gastric juice. The most popular recovery peptide with 100+ preclinical studies showing accelerated healing of tendons, ligaments, muscle, gut lining, and nerves.
CJC-1295 (no DAC)
BA growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
Hexarelin
BThe strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.
Thymosin Alpha-1
AA 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
KPV
C+The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.